RT info:eu-repo/semantics/article
T1 Status of the implementation of pharmacogenetics in clinical practice in Spain: from regional to national initiatives
A1 Apellaniz-Ruiz, Maria
A1 Barrachina, Jordi
A1 Castro-Sanchez, Paula
A1 Comes-Raga, Ana
A1 García-González, Xandra
A1 Gil-Rodriguez, Almudena
A1 Lopez-Lopez, Elixabet
A1 Maroñas, Olalla
A1 Morón, Rocío
A1 Muriel, Javier
A1 Olivera, Gladys G.
A1 Riera, Pau
A1 Saiz-Rodríguez, Miriam
A1 Salvador-Martín, Sara
A1 Sans-Pola, Carla
A1 Tejera-Pérez, Hugo
A1 Velasco-Ruiz, Alejandro
A1 Verde, Zoraida
A1 Wang, Daniel
A1 Rodríguez-Vicente, Ana E.
A1 Nunez-Torres, Rocio
K1 Clinical implementation
K1 Personalized medicine
K1 Pharmacogenetics
K1 Pharmacogenomics
K1 Spanish national healthcare system
K1 Medicina personalizada
K1 Precision medicine
K1 Farmacogenómica
K1 Pharmacogenomics
AB Introduction: Pharmacogenetics (PGx) has the potential to improve patient care, allowing to transform medical interventions by providing personalized therapeutic strategies. Scientific evidence supports the use of PGx in clinical practice and international organizations are developing clinical guidelines to facilitate the utilization of PGx testing. However, clinical implementation of PGx is limited and unequal worldwide. Content: This review summarizes regional and national Spanish initiatives to implement PGx in the clinical practice. Summary and Outlook: Diverse strategies to implement PGx in healthcare are applied across countries or even in the different regions of a specific country. Such was the case of Spain, a European country with 17 Autonomous Regions and two Autonomous Cities, each onewith capacity tomanage theirown healthcare systems. Nevertheless, during the past years, many initiatives and strategies have been launched in Spain to develop different aspects of PGx. Importantly, the National Healthcare System has approved a PGx testing catalogue. This review highlights the crucial work and efforts of scientific societies (like the Spanish Society of Pharmacogenetics and Pharmacogenomics), of experts in PGx, of healthcare providers and of governmental parties in the implementation of PGx to personalize patient therapy, focused in Spain.
YR 2025
FD 2025-11
LK https://hdl.handle.net/10259/11910
UL https://hdl.handle.net/10259/11910
LA eng
NO MA-R received a Postdoctoral Junior Leader–INCOMING Fellowship from “la Caixa” Foundation (ID: 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska Curie grant agreement No. 847648 (fellowship code: LCF/BQ/PI21/11830009). PR has a Juan Rodés fellowship funded by the Instituto de Salud Carlos III (code: JR20/00008). AV-R received a Doctoral Grant FPU by the Spanish Ministry of Science and Innovation (FPU17-04877). The rest of the authors declare no funding.
DS Repositorio Institucional de la Universidad de Burgos
RD 11-jul-2026